Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Thank you for standing by, and welcome to the appellate Pharmaceuticals Third Quarter 2024 earnings conference call. At this time, all participants are in a listen only mode. After the speakers' ...

SG&A expenses were $122.0 million for the third quarter of 2024, compared to $145.7 million for the same period in 2023. The decrease was primarily attributable to decreases in personnel related costs ...

GC Biopharma has partnered with Novelty Nobility to develop new antibody-based treatments for geographic atrophy (GA), a ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...

https://www.tipranks.com/news/company-announcements/kiora-pharmaceuticals-gains-approval-for-phase-2-trial Apellis (APLS) Pharmaceuticals and Sobi announced that ...

Apellis (APLS) Pharmaceuticals and Sobi announced that results from the Phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the American ...

18; Saguaro Gas Piping, LLC. • New/replace/upgrade commercial; 275 N. Saguaro Drive; replace three meter sockets; project closed Sept. 10; Mc3 Electric; Newtown AMD. • Commercial new gas storage; 3395 ...

RBC Capital analyst Lisa Walter initiated coverage of Apellis (APLS) with a Sector Perform rating and $25 price target Complement inhibitors Syfovre and Izervay were approved for geographic ...